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Abstract: INTRODUCTION: Phosphoglucomutase 1 deficiency (PGM1 deficiency) has been identified as
both, glycogenosis and congenital disorder of glycosylation (CDG). The phenotype includes hepatopathy,
myopathy, oropharyngeal malformations, heart disease and growth retardation. Oral galactose supple-
mentation at a dosage of 1 g per kg body weight per day is regarded as the therapy of choice. RESULTS:
We report on a patient with a novel disease causing mutation, who was treated for 1.5 years with oral
galactose supplementation. Initially, elevated transaminases were reduced and protein glycosylation of
serum transferrin improved rapidly. Long-term surveillance however indicated limitations of galactose
supplementation at the standard dose: 1 g per kg body weight per day did not achieve permanent cor-
rection of protein glycosylation. Even increased doses of up to 2.5 g per kg body weight did not result
in complete normalization. Furthermore, we described for the first time heart rhythm abnormalities, i.e.
long QT Syndrome associated with a glycosylation disorder. Mass spectrometry of IGFBP3, which was
assumed to play a major role in growth retardation associated with PGM1 deficiency, revealed no glyco-
sylation abnormalities. Growth rate did not improve under galactose supplementation. CONCLUSIONS:
The results of our study indicate that the current standard dose of galactose might be too low to achieve
normal glycosylation in all patients. In addition, growth retardation in PGM1 deficiency is complex and
multifactorial. Furthermore, heart rhythm abnormalities must be considered when treating patients with
PGM1 deficiency.
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A B S T R A C T
Introduction: Phosphoglucomutase 1 deﬁciency (PGM1 deﬁciency) has been identiﬁed as both, glycogenosis and
congenital disorder of glycosylation (CDG). The phenotype includes hepatopathy, myopathy, oropharyngeal
malformations, heart disease and growth retardation. Oral galactose supplementation at a dosage of 1 g per kg
body weight per day is regarded as the therapy of choice.
Results: We report on a patient with a novel disease causing mutation, who was treated for 1.5 years with oral
galactose supplementation. Initially, elevated transaminases were reduced and protein glycosylation of serum
transferrin improved rapidly. Long-term surveillance however indicated limitations of galactose supplementa-
tion at the standard dose: 1 g per kg body weight per day did not achieve permanent correction of protein
glycosylation. Even increased doses of up to 2.5 g per kg body weight did not result in complete normalization.
Furthermore, we described for the ﬁrst time heart rhythm abnormalities, i.e. long QT Syndrome associated
with a glycosylation disorder.
Mass spectrometry of IGFBP3, which was assumed to play a major role in growth retardation associated with
PGM1 deﬁciency, revealed no glycosylation abnormalities. Growth rate did not improve under galactose sup-
plementation.
Conclusions: The results of our study indicate that the current standard dose of galactose might be too low to
achieve normal glycosylation in all patients. In addition, growth retardation in PGM1 deﬁciency is complex and
multifactorial. Furthermore, heart rhythm abnormalities must be considered when treating patients with PGM1
deﬁciency.
1. Introduction
Phosphoglucomutase 1 deﬁciency (PGM1 deﬁciency) has been de-
ﬁned as a glycogenosis and congenital disorder of glycosylation (CDG)
related to a great variety of biochemical and clinical symptoms.
Phenotypical characterization is still incomplete, pathomechanisms are
only partly understood and although therapeutic approaches have been
proposed, further detailed research and investigation are indispensable.
By converting glucose-1-phosphate into glucose-6-phosphate,
phosphoglucomutase 1 (PGM1) enables the liver to release glucose
from glycogen in order to maintain glucose homeostasis (Fig. 1). In the
reverse reaction, PGM1 catalyzes glucose-6-phosphate conversion into
glucose-1-phosphate for glycogen biosynthesis and is related to the
UDP-galactose pool needed for protein N-glycosylation [1]. PGM1 also
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interacts with Z-band alternatively spliced PDZ motif protein (ZASP) in
heart muscle cells [2].
In this paper, we report on a patient with a novel PGM1 mutation
receiving galactose supplementation expanded by temporary uridine
intake and additional growth hormone therapy. Results of this ﬁrst
long-term surveillance reveal the positive eﬀects and limitations of
galactose supplementation in PGM1 deﬁciency.
Mass spectrometry data on subunits of the growth hormone complex
provide ﬁrst insights into the glycoprotein proﬁle of this PGM1 deﬁ-
cient patient and give explanations on therapeutic limitations.
2. Methods
2.1. Informed consent and ethical approval
Informed consent of the parents was obtained. Ethical approval was
granted by the local Ethics Committee.
2.2. Glycosylation assays
Isoelectric focusing (IEF), as well as immunoprecipitation followed
by sodium dodecyl sulfate-polyacrylamide-gel electrophoresis (SDS-
PAGE) were performed as described elsewhere [1,4].
High performance liquid chromatography (HPLC) of serum trans-
ferrin was carried out following the manufacturer's protocol employing
the “CDT in serum - HPLC” kit from Chromsystems (Gräfelﬁng,
Germany).
Electrospray ionization mass spectrometry (ESI-MS) was performed
as described previously [5].
2.3. Cells and tissues
Patient's leukocytes were obtained and isolated as outlined before
[1].
2.4. Enzyme assays and PGM1 western blotting
A modiﬁed Beutler test using dried blood spots on Guthrie heel-
prick test cards was used. Speciﬁc phosphoglucomutase 1 activity
proﬁle was gained by spectrometric measurement of the enzyme ac-
tivity in extracts of leucocytes as stated elsewhere [1].
Investigation of phosphoglucomutase 1 expression by western
blotting was carried out as described elsewhere [1] using diﬀerent
antibodies (Ab 55,616 and Ab 188,869; Abcam, Cambridge, UK).
2.5. Genetic analysis
Sanger Sequencing of PGM1 was performed on the patient's and the
parents' genomic DNA.
Genomic DNA obtained from patient's leucocytes was isolated and
analyzed for long-QT syndrome (LQTS) gene mutations, in particular
the LQT 1–3, 5–7 and 8 subforms (ion channel genes: KCNQ1, KCNH2,
SCN5A, KCNE1, KCNE2, HCNJ2, CACNA1C) as previously described
[6]. The complete coding sequences were analyzed.
2.6. IGF ternary complex analysis
2.6.1. Aﬃnity puriﬁcation and western blotting of serum IGFBP-3
IGFBP-3 was isolated from 2.5–5 mL serum samples by im-
munoaﬃnity chromatography on columns of anti-IGFBP-3 IgG (R-100,
prepared in-house) immobilized onto agarose (Aﬃ-Gel 10 (Bio-Rad
#1536046)). Bound IGFBP-3 was eluted with 0.1 M acetic acid, 0.5 M
NaCl, pH 2.8. Samples were further puriﬁed on a 4.6 × 250 mm C18
column (Jupiter 5 μm, 300 Å; Phenomenex 00G-4053-E0), using a
15–60% gradient of acetonitrile in 0.1% triﬂuoroacetic acid over
30 min at 1.5 mL/min.
Western blotting was performed as previously described [7].
2.7. IGFBP-3 mass spectrometry
Puriﬁed IGF-BP3 was reduced with dithiothreitol followed by carba-
midomethylation, and then digested with a mixture of trypsin and
Fig. 1. Schematic representation of phosphoglucomutase 1 (PGM1) key role in metabolism and protein interaction.
In PGM1 deﬁciency, malfunction of the enzyme causes a wide range of clinical symptoms such as hepatopathy, uvula biﬁda, myopathy, cardiomyopathy and growth retardation [1].
PGM1 serves as a binding factor to the ZASP in heart muscle cells. The deﬁcient enzyme causes dilated cardiomyopathy [2].
In PGM1 deﬁciency, glucose-6-phosphate (blue) cannot be generated from glycogen, which causes hypoglycemia and exercise- induced rhabdomyolysis [3].
By galactose supplementation (yellow) the PGM1 pathway is bypassed and the formerly deﬁcient protein glycosylation is compensated [1].
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lysylendopeptidase in 0.1 M Tris HCl, pH 8.0. The solution pH was then
adjusted at pH 5.5 and treated with an Arthrobacter neuraminidase for
desialylation. Enrichment of glycopeptides was carried out according to a
method described previously [8]. Brieﬂy, the digest was mixed with a
15 μL packed volume of Sepharose CL4B (GE Healthcare Life Sciences,
Pittsburgh, PA) in 1 mL of an organic solvent of 1-butanol/ethanol/H2O
(4:1:1, v/v). After gentle shaking for 30 min, the gel was washed twice
with the same organic solvent. The gel was then incubated with an aqu-
eous solvent of ethanol/H2O (1:1, v/v) for 5 min, and the solution phase
was recovered and dried using a vacuum concentrator. After drying the
eluate, the enriched glycopeptides sample was dissolved in 1 μL of 0.1%
(v/v) triﬂuoroacetic acid and mixed with 1 μL of 2% (w/v) 2,5-dihy-
droxybenzoic acid dissolved in a 50% (v/v) acetonitrile solution, and then
placed on a sample target and dried for MS. Matrix-assisted laser deso-
rption/ionization (MALDI) time-of-ﬂight (TOF) mass spectrometry (MS)
was carried out on a Voyager DE Pro mass spectrometer with a nitrogen
pulsed laser (337 nm) (AB Sciex, Framingham, MA). Measurements were
carried out in positive ion and linear TOF mode (Supplementary Fig. 13).
2.8. Galactose and uridine therapy
D-Galactose (D-galactose, provided by Dr. Schär Medical Nutrition
GmbH, Germany) dissolved in water was administered at a total dosage
of 1 g per kg body weight per day split into ﬁve separate portions. After
3.5 months, the daily intake was doubled and then further increased up
to 2.5 g per kg body weight another 3 months later.
Uridine (Uridinum, Fagron GmbH&Co. KG, Germany) at a daily
total dosage of 150 mg per kg body weight divided into ﬁve separate
rations was added to the galactose supplement starting from week 38
for a period of 6 weeks.
In week 47, galactose supplementation was interrupted for 10 weeks
and then reinitiated at a daily dosage of 1 g per kg body weight.
Changes in the glycosylation proﬁle of serum transferrin were
monitored by frequent HPLC and IEF. Serum transaminases and blood




The patient is the 10-year-old son of consanguineous Turkish pa-
tients and was born after 39 weeks of gestation. Birth weight was
2810 g (10th percentile) and body length was 48 cm (3rd percentile).
He presented with cleft palate and Pierre-Robin sequence requiring
surgery during the ﬁrst year of life (Supplementary Fig. 1), dysmorphic
ears, ventricular septal defect with spontaneous closure, maldescensus
testis and myopathy. Walking started at the age of 15 months. Auditory
tests were pathological in the newborn period and hearing aids were
necessary up to the age of 4.5 years.
Fine motor skills were impaired. Weakness of legs limited fast
running.
At the age of four, elevated transaminase levels with a GOT of
139 U/L (<45 U/L), GPT of 45 U/L (<40 U/L) and GLDH of 9.8 U/L
(<5 U/L) were detected. Observation of serum transaminases during
the following years showed permanent enzyme elevation with peaks of
GOT at 289 U/L, GPT at 55 U/L and GLDH at 40.9 U/L.
Body length remained below the 3rd percentile and IGF1 and
IGFBP-3 levels were below normal. At the age of 5 2/12 years, the
patient's skeletal age was estimated at 4 years. Growth hormone
therapy (Norditropin) was introduced at the age of 5 and a half years.
Daily dosage was raised from 0.45 mg up to 1 mg (Supplementary
Fig. 2).
Cardiac examination ﬁrst revealed a QTc of 458 ms (reference:
<440 ms), which initially required no treatment. More recent elec-
trocardiogram analysis showed a QTc of 534 ms so that bisoprolol
therapy was introduced. Consequently, QTc in electrode II shortened to
values within upper reference ranges at 440 ms and V2-4 stayed ele-
vated at 483 ms (Supplementary Figs. 3–6).
Echocardiography did not reveal dilated cardiomyopathy but
showed a slightly enlarged left ventricle (LVed 42 mm; +0.4) with a
normal ejection fraction.
Fig. 2. Pedigree of the patient's family.
Sanger sequencing performed on the patient and his consanguineous parents revealed a homozygous 1 base deletion in the phosphoglucomutase 1 gene (c.771delT) resulting in a
frameshift and a premature stop codon further downstream.
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3.2. Glycosylation assays
Isoelectric focusing (IEF), sodium dodecyl sulfate-polyacrylamide-gel
electrophoresis (SDS-PAGE) as well as high performance liquid chroma-
tography (HPLC Chromsystems) of serum transferrin revealed an ab-
normal transferrin glycosylation pattern (Supplementary Fig. 7).
Mass spectrometry (ESI-MS) of serum transferrin showed abnormal
glycoforms, which decreased under galactose treatment (Supplementary
Fig. 8).
3.3. Enzyme assays and western blotting for PGM1
In the modiﬁed Beutler test for PGM1 deﬁciency, all known PGM1
deﬁcient patients showed enzyme activity below 18 U/dL [1]. PGM−
activity in our patient was 10 U/dL.
Phosphoglucomutase 1 activity in the patient's leucocytes was de-
creased (Supplementary Fig. 9).
Western blots for PGM1 and the control protein β-actin revealed the
absence of phosphoglucomutase 1 in the patient's leucocytes
(Supplementary Fig. 10).
3.4. Genetic analysis
Sanger sequencing revealed a homozygous deletion in exon 5
(c.771delT, F257Lfs*20, reference sequence NM_002633.2). Parents
were heterozygous for this mutation (Fig. 2).
Genetic analysis for presence of a congenital Long QT Syndrome
revealed no mutations in the coding sequences of the major cardiac
genes for repolarization, i.e. KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2,
KCNJ2 and CACNA1C.
3.5. Galactose and uridine therapy
HPLC analyses of transferrin glycosylation revealed an improve-
ment of protein glycosylation after three weeks of daily galactose
supplementation (1 g per kg body weight) (Fig. 3).
After four months, HPLC indicated an undulant stagnation of
transferrin glycosylation with tetrasialo-transferrin ﬂuctuating between
70 and 80% (reference: >85%).
Doubling the daily intake to 2 g galactose per kg body weight im-
proved the glycosylation pattern of the patient's serum transferrin.
Further increase to 2.5 g per kg body weight kept the glycosylation
proﬁle ﬂuctuating close to physiological ranges. Complete and steady
correction of deﬁcient glycosylation was not achieved.
Additional supplementation of uridine has been reported to fully
normalize glycosylation in ﬁbroblasts [1], but did not improve the
serum transferrin glycosylation proﬁle in the patient.
Interruption of galactose supplementation resulted in the reoccurrence
of deﬁcient glycosylation patterns comparable to pretreatment values.
Restart of galactose supplement at a dosage of 1 g per kg body
weight per day showed a quick improvement of protein glycosylation,
remaining beneath normal ranges.
Fig. 3. Changes in glutamate-oxaloacetate transaminase (GOT) levels and protein glycosylation under galactose and temporary uridine supplementation monitored by frequent analysis
of aspartate transaminase levels, HPLC and IEF of serum transferrin (Tf).
Elevated aspartate transaminase levels decreased with galactose supplementation and rose during interruption of therapy.
Deﬁcient glycosylation patterns showed quick improvement after galactose intake, but levels of tetrasialo-Tf (blue line) and hypoglycosylated transferrin isoforms (sum of glycoforms
with 0–3 sialic acids, not shown) remained stagnating without reaching physiological rates (reference according to [9]: asialo-Tf: below level of detection, monosial-Tf: below level of
detection, disialo-Tf: 1.1 ± 0.72, trisialo-Tf: ±2.60, tetrasialo-Tf: 89.84 ± 4.16, pentasialo-Tf: 6.4 ± 3.80).
Dosage increase led to nearly normalized rates (tetrasialo-Tf range: light blue range), but failed to entirely correct the glycosylation deﬁciency. We could not show an additional eﬀect of
uridine.
Interruption of galactose supplementation led to pretreatment glycosylation patterns. Partial recovery of transferrin glycosylation was achieved by a restart of galactose therapy at a daily
intake of 1 g per kg body weight.
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Other parameters, such as serum transaminases and antithrombin III
rates, were reduced and remained within physiological ranges most of
the time. After supplement interruption, values returned to pretreat-
ment ranges (GOT 146 U/L (<50 U/L), GPT 61 U/L (<40 U/L)) and
improved quickly after the restart of dietary galactose supplementation
at a daily dosage of 1 g per kg body weight (GOT 44 U/L (<50 U/L),
GPT 15 U/L (<40 U/L)). However, transient elevations of serum
transaminases were observed intermittently during therapy at the
standard dosage.
3.6. Growth hormone therapy
Growth rate was low since birth and remained below the 3rd per-
centile during early childhood (Fig. 4). Growth hormone therapy had a
beneﬁcial eﬀect with catch-up growth reaching the 3rd percentile.
Galactose did not cause further improvement of the growth rate during
the observed interval.
3.7. IGF ternary complex analysis
Whole sera western blots showed typical doublet band for IGFBP-3
(glycosylation isoforms) at about 38–40 kDa, a faint band at about
36 kDa (unknown) and a major proteolysed IGFBP-3 band at about
30 kDa. Analysis revealed normal patterns with no diﬀerence among
the samples (Supplementary Fig. 11).
In the puriﬁed IGFBP-3 western blot, the untreated patient sample
(P1) had an additional band underneath the 30 kDa proteolysed band in
the puriﬁed IGFBP-3, possibly the amino-terminal fragment IGFBP-3
[1–159] [14] (Supplementary Fig. 12). This fragment is expected to
contain glycosylation at sites 1 and 2 (N89 and N109), in pretreatment
sample P1 possibly diﬀerently glycosylated. It was absent in the con-
trols and appeared to decrease when the patient was treated. However,
it was not evident in P1 whole serum.
Mass spectra of tryptic glycopeptides from IGFBP-3 both, before and
during therapy, did not show abnormally glycosylated species (Fig. 5).
Fig. 4. Body height entered in growth curves for Turkish children aged 0 to 18 years according to reference values [10].
At the age of 5 6/12 years, the patient was introduced to growth hormone therapy (orange) gradually increasing the dosage up to 1 mg per kg body weight. Growth rate was improved and
catch-up growth was observed. Additional galactose intake did not show further improvement (green). The patient's calculated target height is indicated by a blue line.
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4. Discussion
Galactose supplementation has been proposed as a treatment option
for PGM1 deﬁciency with reports on favorable eﬀects regarding protein
glycosylation, endocrine malfunctions, hypoglycemic episodes and
growth retardation [1,15,16].
The results of our single case study question the eﬃcacy of the
previously recommended therapeutic regimen and add further im-
portant details to the already varied phenotype observed in PGM1-CDG.
4.1. Eﬀects of galactose therapy
In our patient, glycosylation was not restored completely by treat-
ment with the current standard dosage of 1 g galactose per kg body-
weight per day [15,16]. Even higher doses of up to 2.5 g per kg body
weight per day were not successful in correcting glycosylation perma-
nently.
In SLC39A8 deﬁciency, a disorder of manganese transport and
glycosylation, daily galactose supplementation was increased up to
3.75 g per kg body weight resulting in normalization of the glycosyla-
tion proﬁle without any observable side eﬀects [17]. Given these
ﬁndings, it is possible similar doses might be needed in PGM1 deﬁ-
ciency in order to increase the UDP-galactose pool suﬃciently. This
might achieve the desired correction of serum protein glycosylation and
needs to be evaluated in the future. However, high doses of galactose
may lead to disruption of the Leloir pathway of galactose metabolism
and the accumulation of toxic metabolites, which is why clinical ap-
plication needs to be well-considered [20].
Furthermore, additional uridine substitution showed no positive
eﬀect on our patient. This is in contrast to previously reported ﬁndings
obtained on cultured human ﬁbroblasts in which uridine substitution
was able to improve glycosylation [1]. Besides, negative eﬀects of long-
term uridine administration were observed in murine models. Notably,
long-term uridine application induced glucose intolerance and fatty
liver disease [22]. These ﬁndings warrant cautious application of ad-
ditional uridine substitution in PGM1 deﬁciency, since the potential
eﬀects of uridine application might worse pre-existing symptoms of
PGM1 deﬁciency.
Similarly to previously reported cases [16], levels of initially ele-
vated transaminases improved under galactose intake. Still, transient
elevations were observed intermittently during long-term surveillance.
This ﬂuctuation might also respond to higher doses of galactose as
suggested above.
4.2. Long QT Syndrome in PGM1 deﬁciency— ﬁrst description and possible
link with glycosylation
Cardiac symptoms observed in congenital glycosylation disorders
Fig. 5. Panel A: Schematic representation of IGFBP-3 structure showing glycosylation sites and ALS binding domain. The glycoprotein IGFBP-3 is an important component of the ternary
IGF transport complex (IGF-I/IGF-II, IGFBP-3, ALS) determining the bioavailability of the IGFs [11]. The three N-glycosylation sites are located in the non-conserved central or linker
domain, while the binding site for ALS is located in a highly conserved C-terminal domain [12]. Hypoglycosylated IGFBP-3 shows increased cell binding activity compared to normally
glycosylated protein [13]. Since the same basic amino acids required for cell binding are also responsible for ALS binding, the competition between cell surface molecules and ALS for the
IGFBP-3 binding domain presumably leads to dissociation of the ternary IGF-IGFBP-3 complex [11].
Panel B: Mass spectra of IGFBP-3 in patient's serum before and under galactose supplementation. Mass spectrometry of IGFBP-3 did not detect unglycosylated peptides, neither before nor
under galactose supplementation.
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are usually limited to structural heart disease, most often dilated car-
diomyopathy [24]. To our knowledge, our patient presenting with a
QTc of 534 ms (reference <440 ms) is the ﬁrst case of Long QT Syn-
drome (LQTS) associated with an inborn error of glycosylation. LQTS is
a channelopathy characterized by a prolonged ventricular repolariza-
tion period of the action potential [18]. Correspondent genetic muta-
tions in common LQTS genes were excluded.
Norring et al. already suggested a link between abnormal N-glyco-
sylation and consequently aﬀected electrocardial signaling in CDG [19].
Recent studies now illustrate the impact of aberrant sialylation on
cardiac ion channel gating and action potential. In vitro data combined
with in silico modeling showed that reduced sialylation alters po-
tassium and sodium currents leading to prolonged duration of cardiac
action potential and a shortened refractory period [21].
Thus, the Long QT Syndrome might be attributable to hypoglyco-
sylation in PGM1 deﬁciency. The link between hypoglycosylation and
an impaired conduction system of the heart is highly relevant for
screening and prophylactic therapy in PGM1 deﬁcient patients.
4.3. Growth retardation in PGM1 deﬁciency — need for further research
Most PGM1 deﬁcient patients present with growth retardation and
show reduced levels of IGF-I and its binding protein IGFBP-3 [1]. IGF-
binding proteins carry the majority of IGFs in the circulation thereby
determining bioavailability and extravascular determination [7]. Up to
date, deﬁcient glycosylation of those binding proteins, such as IGFBP-3,
was presumed to cause reduced growth hormone complex stability,
resulting in decreased half-life and concentration in PGM1 deﬁciency
and consequently growth failure [1]. MPI-CDG patients suﬀering from
growth retardation were successfully treated with mannose supple-
mentation improving protein glycosylation, growth hormone levels and
body height [23]. However, we did not observe any positive eﬀects of
galactose substitution on the growth of our patient.
We employed mass spectrometry of the insulin-like growth factor
complex component IGFBP-3 in order to ﬁnd evidence regarding the
current theory of growth retardation in PGM1 deﬁciency. Analysis de-
tected neither unglycosylated peptides containing glycosylation site-1,
or 3, nor abnormal glycoforms at the three glycosylation sites. Thus,
contradicting former hypothesis, sole hypoglycosylation of the growth
factor complex component is not a suitable explication for growth re-
tardation in PGM1 deﬁciency. In fact, it appears to be a complex
etiology compromising glucose metabolism as well as various glyco-
proteins involved in the hormone cascade [25].
However, mass spectrometry appears to be a very useful analytical
method to map the glycoprotein proﬁle of each CDG patients in order to
characterize the individual deﬁcit and – based on that – evaluate eﬀects
of supplementary therapy.
5. Conclusion
The results of this single case study stress the need for in-
dividualized therapy in PGM1 deﬁciency. In our patient, the current
standard dose of galactose did not achieve complete normalization of
glycosylation as well as other laboratory parameters. In addition, the
previously suggested pathomechanism of growth retardation in this
disorder seems to be more complex than thought and might in fact not
be due to abnormal glycosylation of IGFBP3. Finally, Long QT
Syndrome is a novel phenotypical feature of PGM1 deﬁciency and
should be regarded as a potentially life threatening manifestation of this
inborn error of metabolism.
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